Study record · Cerebrolysin
Cerebrolysin for acute ischaemic stroke — Cochrane review
Moderate-certainty evidence found no beneficial effect on all-cause death; non-death attrition evidence very uncertain.
Key result
Moderate-certainty evidence found no beneficial effect on all-cause death; non-death attrition evidence very uncertain.
Study details
Study designSystematic review / meta-analysis of RCTs
PhaseNot applicable
PopulationAdults with acute ischaemic stroke
Sample sizeMultiple trials; SAE analysis 1335
RouteIntravenous
Regimen / exposureVaried; subgroup included 30 mL for 10 days
DurationAcute treatment trials
ComparatorPlacebo / usual care
Primary endpoint / questionMortality, adverse events and functional outcomes
Safety resultTotal SAEs little/no difference, but non-fatal SAEs increased: RR 2.39 (95% CI 1.10–5.23) in 3 trials.
Key limitationsHeterogeneous peptide mixtures/trials; clinical outcome data limited; indication-specific.
Registry / identifierCochrane review